|
|
|
| 【主 题】 ： |
Peficitinib |
| 【联系人名】 ： |
Linna Green |
| 【电子邮件】 ： |
account@bocsci.com |
| 【联系电话】 ： |
15166698109 |
| 【发布日期】 ： |
2016-9-6 |
| 【详细说明】 ： |
Peficitinib, also known as ASP015K and JNJ-54781532,
is a novel potent JAK inhibitor, which demonstrated
potent efficacy in adjuvant-induced arthritis model
in rats. ASP015K inhibited JAK1, JAK2, JAK3 and TYK2
enzyme activities with IC50 values of 3.9, 5.0, 0.71
and 4.8 nM, respectively. ASP015K inhibited the IL-
2-induced proliferation of human T cells with an
IC50value of 18 nM. Moreover, ASP015K was 14-fold
more potent against JAK1/3 than JAK2/2 on the basis
of EPO-induced proliferation of human leukemia
cells. ASP015K has the potential to demonstrate
JAK1/3-mediated immunomodulatory effects without the
occurrence of JAK2-mediated hematopoietic effects.
ASP015K may have potential use in prevention of
rejection in solid organ transplantation; treatment
of psoriasis; treatment of rheumatoid arthritis.
http://www.bocsci.com/peficitinib-cas-944118-01-8-
item-84-462759.html
|
|
|
|
|
English
